14 October 2026
Convatec Group Plc
(“Convatec” or “the Company”)
Director/PDMR Shareholding
The Company was notified on 13 October 2026 that Jens Viebke, Non-Executive Director of the Company, had purchased 24,400 ordinary shares of 10 pence each in the Company (“Shares”) on 13 October 2026.
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
|||||
|
a) |
Name |
Jens Viebke |
||||
|
2 |
Reason for the notification |
|||||
|
a) |
Position/status |
Non-Executive Director |
||||
|
b) |
Initial notification /Amendment |
Initial Notification |
||||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a) |
Name |
Convatec Group Plc |
||||
|
b) |
LEI |
213800LS272L4FIDOH92 |
||||
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the financial instrument, type of instrument |
Ordinary share of 10p each in Convatec Group Plc |
||||
|
Identification code |
GB00BD3VFW73 |
|||||
|
b) |
Nature of the transaction |
Share purchase |
||||
|
c) |
Price(s) and volume(s) |
|
||||
|
d) |
Aggregated information |
|||||
|
- Aggregated volume |
N/A – single transaction |
|||||
|
- Price |
£2.298 |
|||||
|
e) |
Date of the transaction |
2026-10-13 |
||||
|
f) |
Place of the transaction |
XLON |
||||
Enquiries
James Kerton Company Secretary
Email: cosec@convatec.com
Convatec Group Plc’s LEI code is 213800LS272L4FIDOH92
About Convatec
Pioneering trusted medical solutions to improve the lives we touch: Convatec is a global medical products and technologies company, focused on solutions for the management of chronic conditions, with leading positions in Advanced Wound Care, Ostomy Care, Continence Care, and Infusion Care. With over 10,000 colleagues, we provide products and services in around 90 countries, united by a promise to be forever caring. Our solutions provide a range of benefits, from infection prevention, treatment for hard to heal wounds, at-risk skin and ulcerated tissue to supporting debilitating conditions, improved patient outcomes and reduced care costs. Convatec's revenues in 2025 were over $2 billion. The company is a constituent of the FTSE 100 Index (LSE:CTEC). To learn more please visit http://www.convatecgroup.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.